| 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 基础输液(元) | 414,546,403.90 | 818,826,786.72 | 418,097,884.86 |
| 医疗器械(元) | 62,950,939.34 | - | 87,110,865.15 |
| 治疗制剂(元) | 103,133,000.79 | 165,373,883.74 | 88,272,293.08 |
| 腹透液(元) | 178,126,326.09 | 340,242,864.63 | 159,123,185.82 |
| 其他(元) | 12,704,550.47 | 311,812,821.70 | 76,442,080.59 |
| 营业成本(元) | |||
| 基础输液(元) | 252,228,336.22 | 474,227,333.40 | 233,483,449.84 |
| 医疗器械(元) | 49,258,216.70 | - | 75,644,752.66 |
| 治疗制剂(元) | 48,836,091.99 | 57,589,583.62 | 28,923,163.69 |
| 腹透液(元) | 121,982,931.72 | 198,208,616.70 | 92,736,590.99 |
| 其他(元) | 7,891,927.09 | 207,176,444.83 | 48,636,988.55 |
| 毛利(元) | |||
| 基础输液(元) | 162,318,067.68 | 344,599,453.32 | 184,614,435.02 |
| 医疗器械(元) | 13,692,722.64 | - | 11,466,112.49 |
| 治疗制剂(元) | 54,296,908.80 | 107,784,300.12 | 59,349,129.39 |
| 腹透液(元) | 56,143,394.37 | 142,034,247.93 | 66,386,594.83 |
| 其他(元) | 4,812,623.38 | 104,636,376.87 | 27,805,092.04 |
| 毛利率(%) | |||
| 基础输液(%) | 39.16 | 42.08 | 44.16 |
| 医疗器械(%) | 21.75 | - | 13.16 |
| 治疗制剂(%) | 52.65 | 65.18 | 67.23 |
| 腹透液(%) | 31.52 | 41.74 | 41.72 |
| 其他(%) | 37.88 | 33.56 | 36.37 |
| 收入构成(%) | |||
| 基础输液(%) | 53.74 | 50.04 | 50.43 |
| 医疗器械(%) | 8.16 | - | 10.51 |
| 治疗制剂(%) | 13.37 | 10.11 | 10.65 |
| 腹透液(%) | 23.09 | 20.79 | 19.19 |
| 其他(%) | 1.65 | 19.06 | 9.22 |
| 毛利构成(%) | |||
| 基础输液(%) | 55.73 | 49.30 | 52.80 |
| 医疗器械(%) | 4.70 | - | 3.28 |
| 治疗制剂(%) | 18.64 | 15.42 | 16.98 |
| 腹透液(%) | 19.28 | 20.32 | 18.99 |
| 其他(%) | 1.65 | 14.97 | 7.95 |